Recombinant Human Neurofilament light polypeptide(NEFL)

In Stock
Code CSB-EP015688HU
Size US$1726Purchase it in Cusabio online store
(only available for customers from the US)
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP015688HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) NEFL.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP015688HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) NEFL.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names NEFL
Uniprot No. P07196
Research Area others
Alternative Names 68 kDa neurofilament protein; 68kDa Neurofilament; 68kDa neurofilament protein; CMT1F; CMT2E; FLJ53642; Light molecular weight neurofilament protein; NEFL; Neurofilament light; Neurofilament light polypeptide 68kDa; Neurofilament light polypeptide; Neurofilament protein, light chain; Neurofilament subunit NF L; Neurofilament triplet L protein; NF-L; NF68; NFL; NFL_HUMAN
Species Homo sapiens (Human)
Source E.coli
Expression Region 2-543aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 81.4kDa
Protein Length Full Length of Mature Protein
Tag Info N-terminal 10xHis-SUMO-tagged and C-terminal Myc-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Q&A and Customer Reviews


Are both tags, i.e. 10xHis-SUMO tag at the N-terminus and Myc tag at the C-terminus used for purification? Is the SUMO tag removed by SUMO Protease treatment?

Thanks for your inquiry. Here is the informaton about tags:
① The His changes from 6*his to 10*his. The main reason is that 10*His has a stronger affinity for the column material whih is helpful for those proteins that can't attach to the column very well.
It is also helpful for protein purification (The specific adsorption capacity target protein is strong, and the nonspecific adsorption ability of the impurity protein is weak, then we can design a high concentration of midazolam to further remove the impurity protein).
② We add myc-tag at C-terminus. This is mainly for the convenience of customers and we to do WB detection for myc-tag antibody, thus further test the accuracy of the target protein. Although we can also detect His-tag antibodies by WB, but relatively speaking, its specificity is not good as myc-tag.
③ We add thrombin site for all tags. It will be more convenient if you require tag removal later.

I was wondering if you could let me know at what concentration the current lot of CSB-EP015688HU / Recombinant Human Neurofilament light polypeptide(100 µg) is provided.

Thanks for your inquiry. Regarding this item, CSB-EP015688HU, we have the protein both in liquid form and lyophilized form currently.
Liquid form: 0.32mg in stock. Lot number is 03193. The concentration is 0.8mg/ml.
Lyophized form: 2.44mg in stock. Lot number is 03403. The concentration before lyophization is 0.6mg/ml. You could redissolve it to your wanted concentration.

Target Data

Function Neurofilaments usually contain three intermediate filament proteins
Gene References into Functions
  1. NF-L may be involved in severity of neuronal injury following traumatic brain injury PMID: 27819296
  2. CSF neurofilament light chain protein is an accurate marker for distinguishing Alzheimer's disease patients from healthy controls. PMID: 28527630
  3. Cerebrospinal fluid neurofilament protein light is a useful tool for determining disease intensity in frontotemporal dementia and motor neuron disease patients. PMID: 28631955
  4. Our results suggest that plasma NFL levels may not be a useful biomarker for the diagnosis of prodromal and dementia stages of AD. PMID: 28428015
  5. In this Chinese Han population a novel Charcot-Marie-Tooth disease-associated gene mutations of NEFL (c.280C>T) was discovered. PMID: 27862672
  6. We conclude that low BDNF and high LCN2 and NF-L levels are associated with Multiple Sclerosis (MS) pathogenesis, and high IGFBP1level is a biomarker for female MS only, suggesting different MS progression pathways between the sexes. LCN2 is a candidate predictor of response to natalizumab treatment, and NF-L is a candidate predictor of clinically isolated syndrome's (CIS) conversion into MS. PMID: 29108879
  7. This study showed tat Serum NfL concentration is increased in familial Alzheimer disease prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration. PMID: 29070659
  8. Results show that both alphaS and NFL can be phosphorylated by CKII, PLK2 and PLK3, but Ser129 in alphaS is a preferential site for PLK2 and PLK3, demonstrating higher phosphorylation efficiency. Comparatively, CKII preferentially phosphorylates Ser473 in NFL and this site can be phosphorylated by PLK1, 2 and 3, but these enzymes prefer to modify other sites within NFL. PMID: 27503460
  9. fL is a weak independent risk factor in clinically isolated syndromes for conversion to multiple sclerosis. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes. PMID: 27521440
  10. Results from 2 independent prospective cohort studies show that serum NFL is a sensitive and dynamic biomarker for axonal injury in concussive traumatic brain injury. The marker should be useful to detect and monitor CNS injury in concussion PMID: 28404801
  11. Findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-beta-1a. Association with whole brain atrophy and formation of acute white matter lesions has implications to use serum NfL as a biomarker of the overall consequences of brain damage and ongoing disease acti... PMID: 28148632
  12. Higher serum NfL concentrations are associated with more rapid brain atrophy and may therefore reflect disease intensity in dementia (FTD). Because blood sampling is less invasive and has better patient acceptability than lumbar puncture, serum NfL may provide important prognostic information and prove to be a useful outcome measure for clinical trials in FTD. PMID: 27581216
  13. We conclude that the NEFL N98S mutation is associated with a dominant intermediate Charcot-Marie-Tooth disease phenotype characterized by early-onset sensorimotor neuropathy delaying motor milestones, which may evolve into a severe and complex clinical picture including cerebellar ataxia. PMID: 26645395
  14. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection PMID: 26870824
  15. The results showed an important role for miR-25 in regulating NEFL expression in Glioblastoma multiforme. PMID: 26209061
  16. Finally, we demonstrated that NEFL inhibited the NF-kappaB pathway, thereby suppressing the expression of uPA and decreasing NSCLC invasiveness and migration. PMID: 26801564
  17. Cerebrospinal fluid NFL concentration is increased by the early clinical stage of Alzheimer's Disease. PMID: 26524180
  18. The miR-381-NEFL axis is important for temozolomide resistance in glioblastoma multiforme. PMID: 25605243
  19. The results od this study concluded that NEFL E396K mutation may manifest with a novel DI-CMT phenotype, characterized by simultaneous involvement of the peripheral and central nervous system. PMID: 25877835
  20. Suggest monitoring the serum level of antibodies against the NF-L chain as a predictive biomarker of treatment response in multiple sclerosis. PMID: 24515731
  21. a novel heterozygous missense mutation c.1166A>G (p.Y389C) in the gene encoding the light-chain neurofilament protein was identified in 4 patients resulting in hereditary motor and sensory neuropathy with pyramidal signs phenotype. PMID: 25583183
  22. Data suggest that, while lacking a stable structure, NFL-TBS.40-63 peptide (a peptide derived from light neurofilament protein) preferentially binds on a specific single site located near C-terminal end of beta-tubulin. PMID: 26016807
  23. Blood-derived NfL level is an easily accessible biomarker with prognostic value in ALS. PMID: 25934855
  24. Data indicate that the N terminus of Pro-EMAP II binds to its C terminus, arginyl-tRNA synthetase, and the neurofilament light subunit. PMID: 25724651
  25. an NEFL mutation in a family clinically manifesting congenital myopathy PMID: 25264603
  26. NEFL overexpression also enhanced differentiation. PMID: 25312269
  27. This is the first study to suggest blood NFL mRNA as a surrogate marker for early prediction of prediabetic peripheral neuropathy, while NSE mRNA levels may be of no diagnostic value in prediabetic patients. PMID: 24733614
  28. An association was found with high CSF NEFL levels and severity of neurodegenerative diseases and survival. PMID: 25339208
  29. expression of NEFL induces cancer cell apoptosis and inhibits invasion in these cell lines, suggesting that NEFL may play a role in cancer cell apoptosis and invasion. PMID: 23992471
  30. CSF NFL indicates ongoing axonal injury in many neuroasymptomatic HIV patients PMID: 24523921
  31. Our findings reveal an extended phenotype of Charcot Marie Tooth disease 2E caused by an identical missense mutation of the NEFL gene. PMID: 24887401
  32. The expression of two miRNAs (miRNAs miR-b1336 and miR-b2403) whose effect is to stabilize NEFL mRNA, are down regulated in amyotrophic lateral sclerosis. PMID: 24454911
  33. Neurofilament light chain protein NF-L has a dynamic role in the reactive and regenerative changes in axons following injury. PMID: 23802559
  34. Within 7 days after cardiac arrest, serum NF-L is a valuable marker of long-term poor neurological outcome. PMID: 23287695
  35. Increased neurofilament light chain blood levels are associated with neurodegenerative neurological diseases PMID: 24073237
  36. NEFL is downregulated by hypermethylation in breast cancer. PMID: 24026393
  37. CSF neurofilament light chain is elevated in frontotemporal degeneration and correlates with disease severity. PMID: 24242746
  38. The biomarker pattern of neurofilament light in CSF distinguishes between progressive and static neurologic disorders. PMID: 23827424
  39. A group of dysregulated miRNAs directly regulate the NFL mRNA 3'UTR in amyotrophic lateral sclerosis. PMID: 23705811
  40. Anti-NFL antibodies could be surrogate biomarkers of axonal injury in early multiple sclerosis. PMID: 23870535
  41. High CSF NFL levels were found in patients with amyotrophic lateral sclerosis ( PMID: 22680408
  42. Depressed neurofilament expression associates with apolipoprotein E3/E4 genotype in maturing human fetal neurons exposed to HIV-1. PMID: 22302611
  43. NEFL mRNA is ectopically expressed in breast malignancies and could be a potential prognostic factor for early-stage breast cancer patients PMID: 22319610
  44. Identification of gaiting defects combined with previously observed muscle atrophy, reduced axon caliber, and decreased nerve conduction velocity suggests that hNF-L(E397K) mice recapitulate many clinical signs associated with Charcot-Marie-Tooth disease. PMID: 22288874
  45. Cerebrospinal fluid biomarker NF-L in white matter lesions differentiates patients with subcortical vascular disease from those with Alzheimer's. PMID: 21860087
  46. Subjects with APOE epsilon4 have higher CSF NFL levels than non-epsilon4 carriers, only when they do not carry a short poly-T variant of TOMM40, which is associated with later age of onset of AD. PMID: 21983493
  47. Neurofilament light polypeptide (NEFL) was identified as a novel hypermethylated gene associated with resistance to cisplatin-based chemotherapy in cancer of head and neck. PMID: 22246235
  48. Normal cerebrospinal fluid levels of NFL at 12 months post-operatively and beyond suggest the absence of any long-term neuronal damage caused by long-term deep brain stimulation treatment in Parkinson's disease. PMID: 21039366
  49. NFL levels were not significantly increased in multiple sclerosis patients compared with controls and had no relationship to disability or progression PMID: 21197541
  50. While RGNEF and NFL mRNA interact directly in vitro, interestingly they only appear to interact in amyotrophic lateral sclerosis lysates and not in controls PMID: 19488899
  51. Data suggest that the neurofilament light level could be used as a prognostic marker in early relapsing-remitting multiple sclerosis. PMID: 20086018
  52. novel mutation in vocal cord paralysis PMID: 19950375
  53. Nonsense NEFL mutations probably cause a recessive phenotype, in contrast to missense mutations, which cause a dominant phenotype. PMID: 19158810
  54. These results confirm that neurofilaments are the main determinant of axonal caliber and conduction velocity. PMID: 20039262
  55. Mutational anlyses of NF-L gene in Parkinsonian patients revealed three silent DNA changes (G163A, C224T, C487T) in three unrelated patients. Association studies based on these haplotypes found no differences between PD patients and controls. PMID: 12231460
  56. Eight novel sequence variations have been identified in the NF-L gene in patients with Charcot-Marie-Tooth phenotype: 5 variants are polymorphisms, including 3 single nucleotide polymorphisms (SNPs), and 3 other missense mutations have been detected. PMID: 12477167
  57. Selective loss of trans-acting instability determinants of neurofilament L mRNA in amyotrophic lateral sclerosis spinal cord. PMID: 12730211
  58. We report a family with a Pro22Ser mutation in the neurofilament-light gene (NF-L; CMT2E) manifesting electrophysiologically as the demyelinating type 1 CMT (CMT1) and pathologically as an axonopathy with giant axons and accumulation of disorganized NF PMID: 15111691
  59. out of frame mutation does not result in Charcot-Marie-Tooth disease type 2E. PMID: 15654615
  60. Interaction of NF-L with N-methyl-D-aspartate receptor (NMDAR) in a heterologous system causes increased cell surface expression of NMDARs, apparently effected by reduction in ubiquitination state of the NR1 subunit of NMDAR. PMID: 15686490
  61. The mechanism of massive aggregate formation of NF-L Charcot-Marie-Tooth disease mutants (P22S and P22T) is revealed, as well as the effect of phosphorylation at the head domain on aggregate alleviation. PMID: 16452125
  62. Cerebrospinal fluid levels of neurofilament protein L are significantly increased in patients with multiple system atrophy predominated by parkinsonism. PMID: 16678934
  63. This study suggests that this I214M substitution in the NEFL gene was not a direct cause of the disease but could be a polymorphism or possibly a modifier of the CMT phenotype. PMID: 16930284
  64. A subgroup of FTD patients had remarkably high CSF levels of NfL. The levels of CSF NfL were significantly higher in early onset Alzheimer's disease compared to controls PMID: 17290105
  65. The stationary neurofilament (NF) network in axons is a key determinant of half-life and transport rate of endogenous NF-L proteins. PMID: 17475803
  66. results argue against an obvious genotype-phenotype correlation regarding Charcot-Marie-Tooth disease onset, degree of muscle weakness, and nerve conduction slowing caused by NEFL mutations PMID: 17620486
  67. In conclusion, CSF NF-L levels may provide both diagnostic and prognostic information, particularly in SOD1 wt ALS. PMID: 17903209
  68. CSF NFL may serve as a useful marker in monitoring CNS injury in HIV-1 infection and in evaluating CNS efficacy of antiretroviral therapy. PMID: 17923616
  69. Auditory nerve involvement in the presence of normal cochlear outer hair cell activity is asymptomatic in one of two families with CMT disorder with different point mutations(Pro22Ser and Glu397Lys) of the NF-L gene. PMID: 18023247
  70. NEFL Pro22Arg mutation is associated with Charcot-Marie-Tooth disease type 1 PMID: 18758688
  71. alanine at position 148 is essentially required for NF-L self-assembly leading to subsequent filament formation in neuronal cells PMID: 19123978
  72. Our results emphasize the complexity of genotype-phenotype correlations in CMT and underline the possible importance of host factors and gene interactions in the development of clinical phenotypes. PMID: 19286384
  73. cerebrospinal fluid NFL is not a molecular marker of axonal damage for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) probably due to the slow progression of this disease. PMID: 19678766
  74. This protein has been found differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. PMID: 19110265

Show More

Hide All

Involvement in disease Charcot-Marie-Tooth disease 1F (CMT1F); Charcot-Marie-Tooth disease 2E (CMT2E)
Protein Families Intermediate filament family
Database Links

HGNC: 7739

OMIM: 162280

KEGG: hsa:4747

UniGene: Hs.521461

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1